Pacer Advisors Inc. Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

Key Points

• Pacer Advisors Inc. has acquired 301,538 shares of Omnicell, Inc. for approximately $10.54 million, representing about 0.64% ownership of the company.
• Omnicell reported earnings of $0.26 per share for the latest quarter, exceeding estimates, with a year-over-year revenue increase of 9.5%.
• Analysts have varied ratings on Omnicell, with a consensus rating of "Moderate Buy" and an average target price of $45.33.

Pacer Advisors Inc. bought a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 301,538 shares of the company's stock, valued at approximately $10,542,000. Pacer Advisors Inc. owned approximately 0.64% of Omnicell at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Johnson Financial Group Inc. purchased a new position in shares of Omnicell in the 4th quarter valued at about $37,000. Headlands Technologies LLC purchased a new stake in Omnicell during the fourth quarter worth approximately $53,000. Huntington National Bank lifted its stake in Omnicell by 236.4% during the fourth quarter. Huntington National Bank now owns 1,359 shares of the company's stock worth $61,000 after purchasing an additional 955 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Omnicell during the fourth quarter worth approximately $101,000. Finally, Corton Capital Inc. purchased a new stake in Omnicell during the fourth quarter worth approximately $208,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Analyst Ratings Changes

OMCL has been the subject of several recent analyst reports. Wells Fargo & Company boosted their target price on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Bank of America boosted their target price on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Finally, Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $45.33.

Omnicell Price Performance

Shares of OMCL stock traded up $1.35 during mid-day trading on Thursday, hitting $31.05. 423,024 shares of the stock traded hands, compared to its average volume of 562,610. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.74. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 67.51, a price-to-earnings-growth ratio of 8.64 and a beta of 0.76. The company's 50-day simple moving average is $29.20 and its 200-day simple moving average is $33.34. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The company's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.03 EPS. As a group, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.